Doxycycline Effects on Inflammation in Cystic Fibrosis
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
Doxycycline is known to exhibit immune modulatory activities beyond its antibacterial
effects. In particular, doxycycline is a potent inhibitor of matrix metalloproteinase 9,
which is a protease derived largely from neutrophils. Recent studies demonstrate a
significant correlation between pulmonary disease severity and sputum concentrations of MMP-9
in patients with CF. In addition, sputum MMP-9 levels are associated with airway remodeling
in CF.
The goal of this study is to determine the therapeutic potential of doxycycline in modulating
host airway inflammation in patients with CF. Specifically, the study will characterize the
PK /PD of doxycycline, evaluate the safety of short term therapy, and explore the
concentration effect relationship between doxycycline exposure and sputum biomarker levels.